

## MITRE / FLUX NOTES **CONCEPTS** v17.3 – Labs, Clinical Trials

DANIEL REEVES, JUHAN SONIN, 28.May.2019



## I LONGITUDINAL LABS

The number of labs displayed vertically within the window will need to be experimented with and will likely depend at least in part on window size. Here we show 4, but that is likely too few.

Labs



sort also by panel or ....? If by panel, then panel names will be inserted and styled as "starred" is.

In longitudinal table mode, the time window is fixed to whatever fits in the screen, although it can still be panned left and right along the timeline. The picker is gone, and starring can still be done along the title row. Again, starred labs/vitals appear again at the top of the list (not shown).


## Labs



		2017 Mar 10	Oct 22	Dec 22	2018 Feb 2	Feb 26	Mar 2	Mar 15	Apr 10
Blood urea nitrogen	units	4	4	4	4	4	4	4	4
C type lab	units	5	5	5	5	5	5	5	5
D type lab	units		6	6	6		6	6	6
Estrogen	units		7	7	7		7	7	7
F lab	units		1	1	1		1	1	1
Globuglobin	units	3	3	3	3	3	3	3	3
J lab	units	4	10	4	4	4	4	4	4
Ketones	units	5.2	5.2	5.2	5.2	5.2	5.2	5.2	5.2
Lymphomes	units						3	3	
Platelets	units						4	4	
Qubits	units	1	1		1	1	1	1	1
★ Stronomyomes	units	2	2		2	2	2	2	2
T...	units					2.4			

# Several interactions

Mousing over the lab name exposes to option to hide or star the lab. The name in the picker is simultaneously highlighted.



The same is true in the picker.



The user selects a data point, thereby selecting the DATE. This displays all values for that date.



## 2 REVISIT: CLINICAL TRIALS

Clinical Trials

Enrolled (1)

Trial	Start date	End date	Description
PATINA	4 Nov 2018	4 Nov 2018	Metastatic breast cancer trial with drug XYZAB

▼ Potential to enroll (6)

Trial	Pending criteria	
ABRACADABRA	2	
PINTO	3	
Xanpax Phase II	6	
Another trial short name	7	

show 2 hidden trials

show inelligible trials

select a trial at left to see enrollment details

## Clinical Trials

### Enrolled (1)

Trial	Start date	End date	Description
PATINA	4 Nov 2018	4 Nov 2018	Metastatic breast cancer trial with drug XYZAB

### ▼ Potential to enroll (6)

Trial	Pending criteria
ABRACADABRA	2
<b>PINTO</b>	<b>3</b> 
Xanpax Phase II	6
Another trial short name	7

show 2 hidden trials

show inelligible trials

#### PINTO

Primary investigation in nano-tubular oncological treatment

Subjects will be randomized into one of two treatment arms following minimum of 4 and maximum of 8 cycles of induction treatment with anti-HER2 therapy. Arm A subjects will receive the experimental th...

[website](#)

start date: 5 Jun 2019

[ClinicalTrials.gov](#)

enrollment end: 1 May 2019

location: Boston, MA

#### Eligibility requirements [show all 5 criteria](#)

☐ Patient received biopsy confirming breast carcinoma within 3 months of trial start

☐ Not smoker

☐ Not pregnant

✗ Patient is not elligible

+ Insert enrollment in note



# Clinical Trials

## Enrolled (1)

Trial	Start date	End date	Description
PATINA	4 Nov 2018	4 Nov 2018	Metastatic breast cancer trial with drug XYZAB

## ▼ Potential to enroll (6)

Trial	Pending criteria
ABRACADABRA	2
PINTO	3
Xanpax Phase II	6
Another trial short name	7

show 2 hidden trials

show inelligible trials

### PINTO

Primary investigation in nano-tubular oncological treatment

Subjects will be randomized into one of two treatment arms following minimum of 4 and maximum of 8 cycles of induction treatment with anti-HER2 therapy. Arm A subjects will receive the experimental th...

[website](#)

start date: 5 Jun 2019

[ClinicalTrials.gov](#)

enrollment end: 1 May 2019

location: Boston, MA

### Eligibility requirements [hide satisfied criteria](#)

☐ Patient received biopsy confirming breast carcinoma within 3 months of trial start

☐ Not smoker

☐ Not pregnant

☒ Age is over 18 and under 65 (confirmed by user)

☒ Confirmation of estrogen receptor-positive (ER+) invasive carcinoma of the breast (confirmed from record data)

✖ Patient is not elligible

+ Insert enrollment in note

Clinical Trials

Enrolled (1)

Trial	Start date	End date	Description
PATINA	4 Nov 2018	4 Nov 2018	Metastatic breast cancer trial with drug XYZAB

▼ Potential to enroll (6)

Trial	Pending criteria
ABRACADABRA	2
PINTO	3
Xanpax Phase II	6
Another trial short name	7

show 2 hidden trials

show inelligible trials

PINTO

Primary investigation in nano-tubular oncological treatment

Subjects will be randomized into one of two treatment arms following minimum of 4 and maximum of 8 cycles of induction treatment with anti-HER2 therapy. Arm A subjects will receive the experimental th...

website

ClinicalTrials.gov

start date: 5 Jun 2019

enrollment end: 1 May 2019

location: Boston, MA

Eligibility requirements

show all 5 criteria

All criteria are satisfied.

✖ Patient is not elligible

+ Insert enrollment in note